Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
- Prof. Steinman's keynote address at a prestigious scientific meeting highlights the company's research credibility.
- Recognition for Steinman's work may enhance the visibility of Pasithea’s MS treatment efforts.
- PAS-002 program targets an important mechanism in MS, potentially offering innovative treatment options.
- None.
– Prof. Steinman’s groundbreaking research linking Epstein-Barr virus to multiple sclerosis named a runner-up for the 2022 Science Magazine Breakthrough of the Year –
PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the keynote address at the American Association for the Advancement of Science (AAAS) Annual Meeting, on March 4 from 11:30am-12:30pm ET, in Washington DC.
AAAS is the world's largest general scientific society, with over 120,000 members, and is the publisher of the scientific journal Science. Prof. Steinman's research on the link between the Epstein-Barr virus and multiple sclerosis (MS) was a runner-up for the 2022 Science Magazine Breakthrough of the Year.
“I’m honored to be asked to address such an important assembly of scientists and to share insight on this critical work with peers,” commented Dr. Steinman. “Recognition of the work by Science is thrilling because of the attention it brings to our effort to fight MS.”
About PAS-002
The Company’s PAS-002 discovery program aims to develop a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM for the treatment of Multiple Sclerosis. GlialCAM, a CNS protein, found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its structure that mimics an identical component of Epstein-Barr virus nuclear antigen 1 (EBNA-1), which plays a critical role in triggering MS.
About Multiple Sclerosis
Multiple Sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).
About Pasithea Therapeutics Corp.
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), Neurofibromatosis type 1 (NF1) and Noonan syndrome.
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
Email: tiago@pasithea.com
FAQ
What is Pasithea Therapeutics aiming to achieve with PAS-002?
When is Prof. Steinman scheduled to speak at the AAAS Annual Meeting?
What recognition did Pasithea's research on MS receive?
How many people are affected by multiple sclerosis worldwide?
What is the significance of the Epstein-Barr virus in relation to MS?
